Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of dose-intensified R-CHOP14 versus R-CHOP21 in untreated diffuse large B-cell lymphoma
ChiCTR-TRC-11001687Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease-free survival. Started Jan 2011; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR-TRC-11001687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001687.